Corbus Pharmaceuticals
CRBP • NASDAQ
Corbus Pharmaceuticals is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Yuval Cohen, with a market cap of $154.5M.
CEOYuval Cohen
Next Earnings
Upcoming earnings announcement for Corbus Pharmaceuticals
Date
Tuesday, May 5, 2026 (in a month)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$1.22
Earnings History
Past 12 earnings reports for Corbus Pharmaceuticals
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 9, 2026 | Q4 2025 | -$1.25Est: -$1.66 | +24.7% | -Est: $1.1M | -100.0% |  10-K |
| Nov 12, 2025 | Q3 2025 | -$1.90Est: -$1.74 | -9.2% | - | — | 10-Q |
| Aug 5, 2025 | Q2 2025 | -$1.44Est: -$1.42 | -1.4% | - | — | 10-Q |
| May 6, 2025 | Q1 2025 | -$1.39Est: -$1.07 | -29.9% | - | — | 10-Q |
| Mar 11, 2025 | Q4 2024 | -$0.78Est: -$1.22 | +36.1% | - | — | 10-K |
| Nov 7, 2024 | Q3 2024 | -$1.15Est: -$0.95 | -21.1% | - | — | 10-Q |
| Aug 6, 2024 | Q2 2024 | -$0.90Est: -$1.26 | +28.6% | - | — | 10-Q |
| May 7, 2024 | Q1 2024 | -$0.83Est: -$1.52 | +45.4% | - | — | 10-Q |
| Mar 12, 2024 | Q4 2023 | -$1.81Est: -$2.36 | +23.3% | - | — | 10-K/A |
| Nov 7, 2023 | Q3 2023 | -$2.27Est: -$2.06 | -10.2% | - | — | — |
| Aug 8, 2023 | Q2 2023 | -$2.05Est: -$3.10 | +33.9% | - | — | — |
| May 9, 2023 | Q1 2023 | -$4.24Est: -$4.09 | -3.7% | - | — | — |